2024-04-29 09:05Financial Performance - The company reported a total revenue of RMB 10.16 billion for Q1 2024, a decrease of 6.56% year-on-year[5]. - Net profit attributable to shareholders was RMB 609.73 million, down 38.22% compared to the same period last year[5]. - The basic and diluted earnings per share were both RMB 0.23, reflecting a decline of 37.84% year-on-year[5]. - The company achieved operating revenue of 10.157 billion RMB in Q1 2024, a decrease of 6.56% year-on-year, primarily due to a significant drop in revenue from COVID-related products compared to the previous year[12]. - Net profit attributable to shareholders was 610 million RMB, a year-on-year decrease of 38.22%, largely impacted by reduced sales of COVID-related products and amortization from the acquisition of Cenexi[13]. - Operating profit for Q1 2024 was ¥1,021,364,060.98, down 28.5% from ¥1,427,139,292.41 in Q1 2023[23]. - The company reported a net profit margin of 7.75% in Q1 2024, down from 10.24% in Q1 2023[23]. - The total profit for the current period is approximately ¥329.55 million, compared to ¥410.08 million in the previous period, reflecting a decrease of about 19.6%[30]. - The net profit for the current period is approximately ¥329.55 million, an increase from ¥305.40 million in the previous period, indicating a growth of about 7.9%[30]. Cash Flow and Assets - The net cash flow from operating activities increased by 5.05% to RMB 917.31 million[5]. - The company reported a net cash flow from operating activities of 917 million RMB, an increase of 5.05% year-on-year[13]. - In Q1 2024, the company reported operating cash inflow of ¥10.30 billion, a decrease of 13.2% from ¥11.87 billion in Q1 2023[25]. - The company experienced a significant decline in cash inflow from investment activities, totaling ¥376.94 million, down 78.1% from ¥1.72 billion in Q1 2023[25]. - The net cash flow from financing activities was ¥98.64 million, a decrease of 65.0% from ¥281.97 million in Q1 2023[26]. - As of March 31, 2024, the company's total current assets amounted to CNY 33.84 billion, showing a slight increase from CNY 33.79 billion at the end of 2023[21]. - The company's total cash inflow from financing activities was approximately ¥4.56 billion, compared to ¥6.71 billion in the previous period, indicating a decrease of about 32%[32]. Shareholder Information - The largest shareholder, Shanghai Fosun High Technology (Group) Co., Ltd., holds 886,315,955 A shares, representing 33.17% of total shares[9]. - The total number of common stock shareholders at the end of the reporting period was 272,884[8]. - The company’s total shares held by the top ten shareholders accounted for approximately 35.84% of total shares[9]. Product Development and Innovation - The company launched a self-developed lyophilized rabies vaccine and the F-i6000 fully automated chemiluminescence immunoassay analyzer, both of which received approval for market entry in China[13]. - The company is focusing on innovation and product development as part of its strategic transformation[13]. - The company's self-developed biosimilar trastuzumab (Hanquyou) has been approved by the FDA for multiple indications, marking it as the first domestically produced biosimilar approved in China, the EU, and the US[14]. - The Ion bronchial navigation system has received approval from the National Medical Products Administration, enabling more precise and minimally invasive lung cancer diagnostics and treatments[15]. - The company has initiated two Phase III clinical studies for OP0595 in combination with antibiotics targeting adult Gram-negative bacterial infections in China[15]. - The company has received acceptance for four additional indications for its biosimilar adalimumab (HLX04) from the National Medical Products Administration[15]. - The company has established a strategic partnership with Sermonix to develop and commercialize lasofoxifene for at least two ER+/HER2- breast cancer indications in China and Hong Kong[18]. Strategic Initiatives - The company has signed an agreement to establish a Shenzhen biopharmaceutical industry fund with a total commitment of CNY 5 billion, of which the company will contribute CNY 1.5 billion[18]. - The company plans to repurchase shares with a total amount not less than CNY 100 million and not exceeding CNY 200 million within six months, with a maximum price of CNY 30 per share[20]. Asset and Equity Changes - Total assets at the end of the reporting period were RMB 113.75 billion, a slight increase of 0.24% from the previous year[5]. - The company reported a total equity attributable to shareholders of RMB 46.35 billion, an increase of 1.45% year-on-year[5]. - Total liabilities decreased to ¥56,210,115,353.13 from ¥56,853,344,377.17, a reduction of 1.14%[22]. - The company's long-term equity investments increased to CNY 24.11 billion as of March 31, 2024, compared to CNY 23.92 billion at the end of 2023[21]. - The company's goodwill remained stable at CNY 10.85 billion as of March 31, 2024, compared to CNY 10.85 billion at the end of 2023[21].